## **Ostial Stents and Distal Embolic Protection During Renal Stenting**

John R. Laird, MD Professor of Medicine Director of the Vascular Center UC Davis Medical Center

# Limitations of Current Techniques of Renal Stenting

- Inaccurate treatment of the renal ostium
- Inadequate lesion coverage
- Excess contrast use during the procedure
- Distal embolization during the procedure despite a technically successful procedure, 20-30% of patients will have deterioration of renal function



#### **Aorto-ostial Disease**





A -1

### **Techniques of Renal Intervention**

#### **Unique Challenges with Aorto-Ostial Stenting**

#### **Inaccurate Placement**

- Not predictable
- Difficult to visualize the ostium

#### **Geometric Mismatch**

- Cylindrical stent, funnel shaped anatomy
- Incomplete scaffolding

#### **Re-Cross Difficulties**

- Stent damage or migration
- Guidewire entanglement in stent struts



#### BullsEye Ostial Stent System (SquareOne, Inc.)



BullsEye Visualized with CTA

Flared stent tailored to the unique anatomy of the aortoostial junction

> Delivery system enables rapid, precise ostial location



Straight Stent: ~2mm Aortic Protrusion



BullsEye Flare Conformed to Aorta



#### BullsEye Ostial Stent System (SquareOne, Inc.)



#### **Technology Specifications**

Stent	316L BMS
Stent Diameter	5mm, 6mm
Stent Length	15mm
Cell Design	Closed
Dual Balloon Inflation	Locator (Volume) Distal (Pressure)
Guide Compatibility	7F
Usable Length	135cm







#### **BullsEye Stent Procedure**



### **BOSS-1 Study**

Purpose	Evaluate deployment and support of BullsEye Ostial Stent System for renal ostial stenoses
Design	Prospective, non-randomized first in man feasibility study
Control	Historic comparison based on literature review
Size	25 patients; 3 EU Centers (Leipzig, Siegburg, Frankfurt)
Primary Endpoint	<ul> <li>Acute procedural success:</li> <li>Angiographic success (residual % DS&lt;30%)</li> <li>Absence of procedure related (MAE) death, embolic events, TLR</li> </ul>

#### **BOSS-I Demographics & Baseline Characteristics**

Patients (n)	25
Female	72% (18/25)
Age	69 <u>+</u> 10 years
Diabetes	56% (14/25)
Blood Pressure (mm Hg) Systolic	157 ± 22
Diastolic	82 ± 10
Serum Creatinine (µmol/l)	$100 \pm 43$
Kidney Length (cm)	$10.0 \pm 0.8$
Target Lesion Location (per patient) Right Kidney Left Kidney	44% (11/25) 56% (14/25)
Target Lesion Characteristics (per procedure) Diameter stenosis Target vessel angle	82% ± 9% 81° ± 9°
Reference vessel diameter	6.1mm ± 0.3mm
	BullsEy

e

#### **BOSS-I Acute Results**

Technical Success	100% (25/25)
Acute Procedural Success	100% (25/25)
Procedural Complications (dissection, thrombosis, perforation)	0% (0/25)
Major Adverse Events (death, target lesion revascularizations, embolic events)	0% (0/25)
Procedure time (mean)	26 minutes
Successful stent positioning & deployment (angiographic confirmation)	100% (25/25)
Successful re-cross of lesion/stent	100% (25/25)
	BullsEye

#### **BOSS-I 12M Results**

MAE (%)	8.0 (2/25)	
Death	0% (0/25)	
TLR (189 and 257 days post treatment)	8.0% (2/25)	
Embolic Events	0% (0/25)	
Blood Pressure (mm Hg)	Baseline	12 Months
Systolic	157 ± 22	141 ± 18
Diastolic	82 ± 10	$83 \pm 8$
Antihypertensive Medications	$3.0 \pm 1.6$	$2.5 \pm 1.4$
Serum Creatinine (µmol/l)		103 ± 34

#### **Post Procedure Result**



#### **Post Procedure Result**





#### Summary

Primary endpoint of Acute Procedural Success met in 100% of cases (24/24)

No observations of geographic miss or stent protrusion into aorta

Flared stent enabled immediate re-cross in all cases

Promising response at 12 months with regards to restenosis and BP response

# **Distal Embolic Protection in RAS**





#### **Current Challenges**

 No device specifically designed for renal embolic protection

Anatomic challenges

- Early renal artery bifurcation
- Large diameter renal artery
- Short length of main renal artery
- Increased procedural complexity



#### **Optimal Renal EPD?**



#### **Distal Filtration**

# Enables maintenance of flow throughout the procedure

#### May allow small but important particles through



Renal Artery Stenting with EP in Patients with Ischemic Nephropathy

83 arteries treated in 63 consecutive patients from May 2002 to February 2005

All patients had baseline CRI with a documented decline in renal function over the preceding 6 months

CE-MRA used in the work-up in all patients

All patients had an identical "primary filter passage" technique and stenting

All patients had a minimum 6 months follow up

Holden, et al. Kidney International, 2006

#### **Filter Contents**

(in pts that did not deteriorate)

#### Macroscopic emboli present in 38/63 filters (60%)

Filter contents	Improved	Stabilized or Unchanged Decline	Total (%)
Positive	20	18	38 (60%)
Negative	5	20	25 (40%)
Total	25	38	<b>63</b> (100%)

Even Patients with positive filter contents had significantly improved outcome (p= 0.01)

Holden, et al. Kidney International, 2006

## Renal Artery Stenting with EP in Patients with Ischemic Nephropathy

#### Level of pre-intervention CRI

	Mild	Moderate	Severe	Total
Improved	12(52%)	8(32%)	5(33%)	25(40%)
Stabilized	11(48%)	15(60%)	10(67%)	36(57%)
Unchanged decline	0(0%)	2(8%)	0(0%)	2(3%)
Total	23	25	15	63

97% of patients had improved or stabilized renal function at 6months

Holden, et al. Kidney International, 2006

#### **Fibernet-Lumen Biomedical**

- Fiber based filter
- Low crossing profile
- 100 micron
- Vessel conformable
- Aspiration and retrieval required
- EPIC- US pivotal trial
- RETRIEVE-US IDE



### The FORTRESS Trial

20 patient feasibility trial
5 US sites
Trial Sponsor: VIVA Physicians

#### Conclusions

The Bullseye ostial stent system has the ability to improve the results of renal stenting by increasing the accuracy stent placement, reducing contrast use, and improving ostial coverage

Embolic protection has the potential to increase the safety of the procedure and better protect the kidney against the consequences of distal embolization